{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:45Z","timestamp":1792515765189,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Lessons Learned<\/jats:title>\n                    <jats:p>TKM-080301 showed a favorable toxicity profile at the studied dose. TKM-080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular carcinoma compared with historical control. Preliminary antitumor activity as shown in this early-phase study does not support further evaluation as a single agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polo-like kinase 1 (PLK1) is overexpressed in hepatocellular carcinoma (HCC). Knockdown of PLK1 expression by PLK1 small interfering RNA (siRNA) in an HCC cell line showed reduced expression in RNA-induced silencing complex and a reduction in cell proliferation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 3 + 3 dose escalation plus expansion cohort at the maximum tolerated dose (MTD) was implemented. Patients with HCC, Eastern Cooperative Oncology Group (ECOG) performance status \u22642, and Child-Pugh score A received TKM-080301 as an intravenous infusion once every week for 3 consecutive weeks, repeated every 28 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study enrolled 43 patients. The starting dose of TKM-080301 was 0.3 mg\/kg, and MTD was declared at 0.75 mg\/kg. Following the development of grade 4 thrombocytopenia in two subjects on the expansion cohort, the MTD was redefined at 0.6 mg\/kg. Four patients did not have any evaluable postbaseline scan. Of the other 39 subjects who had received at least 0.3 mg\/kg, 18 subjects (46.2%) had stable disease (SD) by independent RECIST 1.1 criteria. By Choi criteria, eight subjects (23.1%) had a partial response (PR). For 37 assessable subjects, with 2 subjects censored, median progression-free survival (PFS) was 2.04 months. Median survival for the whole study population was 7.5 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TKM-080301 was generally well tolerated. In this early-phase study, antitumor effect for TKM 080301 was limited. Further evaluation as a single agent in large randomized trials is not warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0838","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T15:04:20Z","timestamp":1546268660000},"page":"747-e218","source":"Crossref","is-referenced-by-count":103,"title":["An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma"],"prefix":"10.1093","volume":"24","author":[{"given":"Imane","family":"El Dika","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Modiano","sequence":"additional","affiliation":[{"name":"Arizona Oncology Associates, PC, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Freilich","sequence":"additional","affiliation":[{"name":"Kansas City Research Institute, LLC, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Chao","sequence":"additional","affiliation":[{"name":"Taipei Medical University, Shuang-Ho Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Brown","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., Warminster, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Knox","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[{"name":"Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[{"name":"Queen Mary Hospital, Hong Kong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,31]]},"reference":[{"key":"2021122507020976300_R1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2021122507020976300_R2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrm1401","article-title":"Polo-like kinases and the orchestration of cell division","volume":"5","author":"Barr","year":"2004","journal-title":"Nat Rev Mol Cell Bio"},{"key":"2021122507020976300_R3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","article-title":"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo","volume":"17","author":"Steegmaier","year":"2007","journal-title":"Curr Biol"},{"key":"2021122507020976300_R4","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/sj.onc.1210355","article-title":"Rational combinations of siRNAs targeting Plk1 with breast cancer drugs","volume":"26","author":"Spankuch","year":"2007","journal-title":"Oncogene"},{"key":"2021122507020976300_R5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1634\/theoncologist.2013-0114","article-title":"Alternative Response Criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"19","author":"Ronot","year":"2014","journal-title":"The Oncologist"},{"key":"2021122507020976300_R6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122507020976300_R7","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3748\/wjg.v18.i27.3527","article-title":"Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma","volume":"18","author":"Mok","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2021122507020976300_R8","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1158\/1078-0432.CCR-08-0626","article-title":"Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"suppl 8","key":"2021122507020976300_R9","doi-asserted-by":"crossref","first-page":"2829A","DOI":"10.1158\/1538-7445.AM2011-2829","article-title":"Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1","volume":"71","author":"Semple","year":"2011","journal-title":"Cancer Res"},{"key":"2021122507020976300_R10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrd1345","article-title":"siRNAs: Applications in functional genomics and potential as therapeutics","volume":"3","author":"Dorsett","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2021122507020976300_R11","first-page":"135","article-title":"Passive tumor targeting of soluble macromolecules and drug conjugates","volume":"9","author":"Seymour","year":"1992","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2021122507020976300_R12","first-page":"3752","article-title":"Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size","volume":"55","author":"Yuan","year":"1995","journal-title":"Cancer Res"},{"key":"2021122507020976300_R13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1172\/JCI37515","article-title":"Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice","volume":"119","author":"Judge","year":"2009","journal-title":"J Clin Invest"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/747\/41918069\/oncolo_24_6_747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/747\/41918069\/oncolo_24_6_747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T07:49:21Z","timestamp":1662709761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/747\/6439385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,31]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0838","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2018,12,31]]}}}